Vaccines

Pricing and Reimbursement (P&R) Strategy

Create a P&R strategy that meets your business goals

P&R strategies that deliver commercial success

Alira Health provides a range of P&R strategies and solutions that deliver commercial success, including:
  • A comprehensive, structured overview of your target market characteristics (e.g., public, private, travel, occupational health, including epidemiological situation)
  • Recommendations for different pricing scenarios for different patient groups
  • Analysis and recommendations for reference prices strategies for vaccines
  • Development of a pricing simulator and assessment of pricing influences across your target market
  • Creation of a commercialization strategy in different market segments
  • KOL analysis and KOL feedback collection to support reimbursement negotiations

Why choose Alira Health?

When you partner with us, you’ll benefit from:

  • Access to a multidisciplinary team of vaccine experts, economists, regulatory experts, and strategic consultants
  • A strategic approach to P&R strategy development with a focus on long-term impact
  • Access to a full continuum of services, such as patient engagement, regulatory, and much more
  • Extensive global network of external experts

Working together to transform healthcare

Whether you need to understand which asset best aligns with your long-term strategy, which new market or therapeutic area to explore, or how to expand into another sector, we are ready to help you lead the way.

Contact us
Bernd Schollmeier
Bernd Shollmier
Vice President of Global Market Access Vaccines
We are seeing a lot of traction in the industry, as well as interest in vaccine production. To support companies in a challenging payer environment, we created a dedicated vaccine division in our Global Market Access department to provide a variety of solutions that maximize patient access and the gross-to-net value of the product across the full product lifecycle.

Related News

Blog April 17, 2024
The Challenges for Medtech in a Complex Regulatory Landscape in 2024
Learn more about what manufacturers in the US and Europe should consider when developing their regulatory strategies and prioritizing their target markets from regulatory affairs expert Mercè Guerra.
Medical Devices MedTech Regulatory
Blog March 18, 2024
WHO Model Lists of Essential Medicines: What You Need to Know 
Our Market Access experts share the importance of the EML for pharma companies and four best practices for a successful application, based on our extensive experience in interactions with the WHO.
Market Access
Events March 7, 2024
MedTech Impact Symposium & Gala 2024
Look for us at the 2024 MassMedic Medtech Impact Symposium and let's connect on the four focus tracks: Maternal Health, Cardiac Health, Diabetes and Musculoskeletal Health.
Medical Devices MedTech
Blog February 27, 2024
The 2024 Global Medtech Contract Manufacturing Report: Executive Summary
Executive summary of our 2024 global medtech contract manufacturing report detailing global trends and investment activity and in-depth analysis of the European outsourcing market.
CDMO MedTech
News February 26, 2024
Alira Health Releases The 2024 Global Medtech Contract Manufacturing Report
Alira Health announced the release of the 2024 Global Medtech Contract Manufacturing Report. This report offers a comprehensive analysis of trends in the global medtech contract manufacturing(...)
CDMO MedTech
Publications February 25, 2024
The 2024 Global Medtech Contract Manufacturing Report
Discover the trends in the world of medical device CDMOs and their meaning for the industry in 2024 and beyond.
CDMO MedTech
Multimedia February 22, 2024
Robotic-assisted Surgery in Orthopedic Procedures: Current Landscape and 2024 Outlook
This webinar replay investigates the current RAS landscape with specific focus on adoption drivers, market dynamics, access challenges and more.
MedTech Orthopedic Robotic-Assisted Surgery (RAS)
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.